EFFECTS OF A THYMIC HORMONE, THF, ON TUMOR-BEARING MICE AND TUMOR-RESECTED MICEGABIZON A; TRAININ N.1981; CANCER IMMUNOL. IMMUNOTHER.; ISSN 0340-7004; DEU; DA. 1981; VOL. 10; NO 2-3; PP. 105-111; BIBL. 24 REF.Article

Tailoring liposomes for cancer drug delivery : from the bench to the clinic = Préparation de liposomes pour la délivrance de médicaments anticancéreuxGABIZON, A.Annales de biologie clinique (Paris). 1993, Vol 51, Num 9, pp 811-813, issn 0003-3898Conference Paper

REGULATORY ACTION OF THE THF ON T-CELL REACTIVITY TO MITOGENSGABIZON A; TRAININ N.1980; THYMUS; ISSN 0165-6090; NLD; DA. 1980; VOL. 1; NO 4-5; PP. 225-239; BIBL. 21 REF.Article

ENHANCEMENT OF GROWTH OF A RADIATION-INDUCED LYMPHOMA BY T CELLS FROM NORMAL MICEGABIZON A; TRAININ N.1980; BR. J. CANCER; ISSN 0007-0920; GBR; DA. 1980; VOL. 42; NO 4; PP. 551-558; BIBL. 29 REF.Article

KINETICS OF THE RESPONSE OF SPLEEN CELLS FROM TUMOR-BEARING ANIMALS IN AN IN VIVO TUMOR NEUTRALIZATION ASSAY.GABIZON A; SMALL M; TRAININ N et al.1976; INTERNATION. J. CANCER; SWITZ.; DA. 1976; VOL. 18; NO 6; PP. 813-819; ABS. FR.; BIBL. 12 REF.Article

E-ROSETTES IN HUMAN LYMPHOCYTES. ENHANCEMENT AND DEPRESSION AFTER INCUBATION OF LYMPHOCYTES WITH PAPAIN AND TRYPSIN.GARRIDO F; GABIZON A; OSORIO C et al.1975; REV. ESP. FISIOL.; ESP.; DA. 1975; VOL. 31; NO 3; PP. 145-149; BIBL. 11 REF.Article

Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomesGABIZON, A. A.Cancer research (Baltimore). 1992, Vol 52, Num 4, pp 891-896, issn 0008-5472Article

CONTRASTING EFFECTS OF ACTIVATED AND MONACTIVATED MACROPHAGES AND MACROPHAGES FROM TUMOR-BEARING MICE ON TUMOR GROWTH IN VIVOGABIZON A; LEIBOVICH SJ; GOLDMAN R et al.1980; J. NATL. CANCER INST.; ISSN 0027-8874; USA; DA. 1980; VOL. 65; NO 5; PP. 913-920; BIBL. 23 REF.Article

ENHANCEMENT OF E-ROSETTES FORMATION AFTER TREATMENT OF LYMPHOCYTES WITH PAPAIN = AUGMENTATION DE LA FORMATION DE ROSETTESE APRES TRAITEMENT DES LYMPHOCYTES PAR LA PAPAINEGARRIDO F; GABIZON A; OSORIO C et al.1974; REV. ESP. FISIOL.; ESP.; DA. 1974; VOL. 30; NO 4; PP. 303; BIBL. 4REF.Article

Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumorsGABIZON, A; PAPAHADJOPOULOS, D.Proceedings of the National Academy of Sciences of the United States of America. 1988, Vol 85, Num 18, pp 6949-6953, issn 0027-8424Article

LIPOSOMES AS IN VIVO CARRIERS OF ADRIAMYCIN: REDUCED CARDIAC UPTAKE AND PRESERVED ANTITUMOR ACTIVITY IN MICEGABIZON A; DAGAN A; GOREN D et al.1982; CANCER RESEARCH; ISSN 0008-5472; USA; DA. 1982; VOL. 42; NO 11; PP. 4734-4739; BIBL. 28 REF.Article

The role of surface charge and hydrophilic groups on liposome clearance in vivoGABIZON, A; PAPAHADJOPOULOS, D.Biochimica et biophysica acta. Biomembranes. 1992, Vol 1103, Num 1, pp 94-100, issn 0005-2736Article

Reduced UV-induced degradation of doxorubicin encapsulated in polyethyleneglycol-coated liposomesBANDAK, S; RAMU, A; BARENHOLZ, Y et al.Pharmaceutical research. 1999, Vol 16, Num 6, pp 841-846, issn 0724-8741Article

Systemic administration of doxorubicin-containing liposomes in cancer patients: a phase I studyGABIZON, A; PERETZ, T; SULKES, A et al.European journal of cancer & clinical oncology. 1989, Vol 25, Num 12, pp 1795-1803, issn 0277-5379, 9 p.Article

Pegylated liposomal doxorubicin (doxil): Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m²SAFRA, T; MUGGIA, F; JEFFERS, S et al.Annals of oncology. 2000, Vol 11, Num 8, pp 1029-1033, issn 0923-7534Article

Optimization and upscaling of doxorubicin-containing liposomes for clinical useAMSELEM, S; GABIZON, A; BARENHOLZ, Y et al.Journal of pharmaceutical sciences. 1990, Vol 79, Num 12, pp 1045-1052, issn 0022-3549, 8 p.Article

Enhancement of antitumor activity of polyethylene glycol-coated liposomal doxorubicin with soluble and liposomal interleukin 2CABANES, A; EVEN-CHEN, S; ZIMBEROFF, J et al.Clinical cancer research. 1999, Vol 5, Num 3, pp 687-693, issn 1078-0432Article

Polyethylene glycol-coated (pegylated) liposomal doxorubicin : Rationale for use in solid tumoursGABIZON, A; MARTIN, F.Drugs (Basel). 1997, Vol 54, pp 15-21, issn 0012-6667, SUP4Article

Liposome longevity and stability in circulation : Effects of the in vivo delivery to tumors and therapeutic efficacy of encapsulated anthracyclinesGABIZON, A; CHEMLA, M; TZEMACH, D et al.Journal of drug targeting. 1996, Vol 3, Num 5, pp 391-398, issn 1061-186XArticle

Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomesGABIZON, A; CATANE, R; UZIELY, B et al.Cancer research (Baltimore). 1994, Vol 54, Num 4, pp 987-992, issn 0008-5472Article

Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (doxil) in metastatic breast carcinomaLYASS, O; UZIELY, B; BEN-YOSEF, R et al.Cancer. 2000, Vol 89, Num 5, pp 1037-1047, issn 0008-543XArticle

The influence of physical characteristics of liposomes containing doxorubicin on their pharmacological behaviorGOREN, D; GABIZON, A; BARENHOLZ, Y et al.Biochimica et biophysica acta. 1990, Vol 1029, Num 2, pp 285-294, issn 0006-3002, 10 p.Article

Superior therapeutic activity of liposome-associated adriamycin in a murine metastatic tumour modelGABIZON, A; GOREN, D; FUKS, Z et al.British journal of cancer. 1985, Vol 51, Num 5, pp 681-689, issn 0007-0920Article

Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation timesGABIZON, A; SHIOTA, R; PAPAHADJOPOULOS, D et al.Journal of the National Cancer Institute. 1989, Vol 81, Num 19, pp 1484-1488, issn 0027-8874Article

Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid : pharmacokinetic studies in rodents and dogsGABIZON, A. A; BARENHOLZ, Y; MEIR BIALER et al.Pharmaceutical research. 1993, Vol 10, Num 5, pp 703-708, issn 0724-8741Article